Magenta Therapeutics (MGTA) just recently mentioned financial outcomes for the 3rd quarter ended September 30, 2019 and current service highlights.
On the other end, the stock has actually been kept in mind 120.92% away from the low price over the last 52-weeks. The stock altered -0.85% to recent value of $13.94.
Cash Position: Cash, money equivalents and valuable securities since September 30, 2019, were $160.6 M contrast to $142.6 M on December 31, 2018. Magenta prepares for that its money, money equivalents and marketable securities will be adequate to money operations and capital investment into the 2nd half of 2021.
Research Study and Development Expenses: Research and development costs were $16.5 M in the 3rd quarter of 2019, contrast to $11.4 M in the third quarter of 2018. The boost was driven primarily by investments in clinical activities for MGTA-145, in addition to making related to our client preparation programs.
General and Administrative Expenses: General and administrative expenses were $6.1 M for the 3rd quarter of 2019, contrast to $5.3 M for the third quarter of 2018. The increase was mostly Because of a raise in professional fees and center expenses related to the development of the Company.
Bottom line: Net loss was $ 21.0 M for the third quarter of 2019, contrast to bottom line of $16.0 M for the third quarter of 2018.
The rate continued of -5.45% from the mean of 20 days, 4.87% from mean of 50 days SMA and performed 6.98% from mean of 200 days rate. Companys performance for the week was 3.41%, -0.43% for month and YTD efficiency remained -8.05%.